Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 26, 2025 08:00 ET | Source: Incannex Healthcare

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) is pleased to report positive data from its Phase 2...
September 20, 2021 08:30 ET | Source: Psychable, Inc.

This Magic Mushroom Day, Communities Across the Globe Celebrate the Transformative Healing Power of Using Psychedelics as Medicine

LOS ANGELES, Sept. 20, 2021 (GLOBE NEWSWIRE) -- September 20 is Magic Mushroom Day and this year, communities across the world are celebrating the psychedelic renaissance. As research, clinical...
July 07, 2021 11:45 ET | Source: Reset Pharmaceuticals, Inc.

UPDATE -- Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in...
July 07, 2021 07:00 ET | Source: Reset Pharmaceuticals, Inc.

Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in...